Dear Editor,

We are glad that we have this opportunity and that you are considering our manuscript to be published in the World Journal of Psychiatry. The revision process and all suggestions have greatly improved our manuscript.

We tried to answer all reviewer's comments, point by point and marked them in the text with yellow. Some references were added and also marked in the text.

**Reviewer #1**

1. **Section "Introduction", the first paragraph:** "Recently, it has been discussed that the schizophrenia prevalence rate in the population remains stable..."
   • Percentage of schizophrenia prevalence rate (estimated)?

   We have now added exact percentages per the reviewer's suggestion. We have now also change this reference.

2. **Section: "Introduction", second paragraph:** "Furthermore, genome-wide association studies in schizophrenia emphasized similar genetic backgrounds with some immunological properties and genetic overlap with breast carcinoma."
   • Is there an estimated percentage of genetic overlap in literature?

   There is an estimated percentage of genetic overlap and we have now added this number in the text, but in the text below (Section: “Breast cancer risk and schizophrenia”, first paragraph). In addition, we have firstly introduced the reference pointing out the genetic overlap of schizophrenia and breast carcinoma.

3. **Section: "Breast cancer risk and schizophrenia", first paragraph:** "Disturbingly, approximately 2.1 million new cases of female breast cancer were diagnosed in 2018, accounting for nearly one in four cancer cases in women, and approximately 630 000 with lethal outcomes."
   • These statistics about breast cancer refers to Serbia? Europe? Worldwide? Please specific. Also, I suggest eliminating the word "female", data includes all cases (women and men with breast cancer).
We have now specified that this statistics reflect worldwide data, also, we eliminate the word female, all per the reviewer's suggestions.

4. Section: "IL-33 role in neuroinflammation and neurodegeneration", first paragraph: "IL-33 is an alarmin, a damage...")
   • In some parts of the manuscript authors mentioned that IL-33 is an alarmin, also is a multifunctional cytokine. Can authors clarify terms? For example: "IL-33 is a multifunctional cytokine and also an alarmin" (referring that an alarmin is one of the cytokine functions).

In the first paragraph of the section: "IL-33 role in neuroinflammation and neurodegeneration", we have first introduced the reader to the fact that IL-33 is a multifunctional cytokine and also an alarmin.

5. Section: "IL-33 role in neuroinflammation and neurodegeneration", third paragraph: "Up-regulated expression of IL 33 in peripheral...")
   • Homogenize the term "IL-33" in all manuscripts.

Abbreviation IL-33 has now been uniformly used in the whole manuscript.

6. Section: "IL-33 in therapeutical strategies for breast cancer in schizophrenia", first paragraph: "Some antipsychotics may induce a higher level of prolactin, so-called "prolactin-raising", and consequently an increased risk of breast cancer, promoting carcinogenesis and transition to invasive carcinoma".
   • Add: "Previously, trials showed that some antipsychotics...").

This sentence is now revised per the reviewer's recommendation.

7. Section: "Concluding remarks", first paragraph: "Prevention strategies for the breast carcinoma onset in female schizophrenia patients could..."
   • I suggest delete “female” and consider “schizophrenia patients”

This sentence is now revised per the reviewer's recommendation.
**Other specific requirements**

1. **Title:** Please spell out any abbreviation in the title. Abbreviations are not permitted.

   We removed abbreviations in the title.

2. **Running title:** Please shorten the running title to no more than 6 words. Abbreviations are permitted.

   We have now provided a running title.

3. **Abstract:** Abbreviations must be defined upon the first appearance in the Abstract.

   We have now defined abbreviations upon the first appearance in the Abstract.

4. **Key words:** Abbreviations must be defined upon the first appearance in the Key words.

   We have defined abbreviations upon the first appearance in the Key words.

5. **Core tip:** Abbreviations must be defined upon the first appearance in the Core tip.

   We have defined abbreviations upon the first appearance in the Core tip.

6. **Main Text:** Abbreviations must be defined upon the first appearance in the Main Text.

   We have defined abbreviations upon the first appearance in the Main text.

7. **Figures:** Please verify the abbreviations used in figures and define them (separated by semicolons) at the end of the figure legend or table; for example, **BMI:** Body mass index; **CT:** Computed tomography.
We have verified the abbreviations used in figures and defined them at the end of the figure legend.

**Editorial Office comments**

1. **The “Author Contributions” section is missing. Please provide the author's contributions.**

   We have now provided the author’s contributions in the manuscript.

2. **The authors did not provide the approved grant application form(s). Please upload the approved grant application form(s) or funding agency copy of any approval document(s).**

   We have uploaded the approved grant application form.

3. **Please add a table/figure to this review.**

   We have now added two figures to the manuscript.

**Company editor-in-chief comments**

1. **Before final acceptance, the author(s) must add a table/figure (medical imaging) to the manuscript.**

   We have now added two figures to the manuscript.